Loading...

Acer Therapeutics Inc.

ACER•NASDAQ
Healthcare
Biotechnology
$0.66
$-0.14(-17.95%)

Acer Therapeutics Inc. (ACER) Stock Overview

Explore Acer Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.3/100

Key Financials

Market Cap0
P/E Ratio-0.37
EPS (TTM)$-1.93
ROE3.01%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.62

ACER Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Acer Therapeutics Inc. (ACER) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.62.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.37 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ACERStats details for ACER are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ACERAnalyst Recommendations details for ACER are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

CEO

Christopher Schelling

Employees

30

Headquarters

One Gateway Center, Newton, MA

Founded

2004

Frequently Asked Questions

;